Ligand ID: 08H Drugbank ID: DB00404(Alprazolam) Indication:For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 619ASN A 695PHE A 753VAL A 785 | 1.74A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | ASN A 543VAL A 667SER A 672TYR A 674 | 1.73A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | ASN A 314PHE A 326HIS A 347TYR A 346 | 1.72A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 745PHE A 741VAL A 720TYR A 719 | 1.72A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 192PHE A 219HIS A 99TYR A 217 | 1.61A | 19.4720.38 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | TRP A 162LEU A 131LEU A 247ILE A 171 | 1.55A | 9.27 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO D 121LEU C 35LEU C 55ILE D 120 | 1.73A | 21.00 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 7 | PRO A 665LEU A 611LEU A 650ILE A 664 | 1.56A | 6.19 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | ASN A 532PHE A 543VAL A 539SER A 325 | 1.38A | 17.6317.23 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 7 | PRO A1053LEU A 822LEU A 938ILE A 805 | 1.59A | 7.42 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | ASN C 532PHE C 543VAL C 539SER C 325 | 1.41A | 17.6317.23 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 8 | TYR C 451PHE C 497VAL C 510TYR C 508 | 1.66A | 15.9916.74 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6w41 | CR3022 FAB HEAVYCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR C 369PHE C 377VAL C 382SER H 96 | 1.51A | 15.9916.74 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 8 | ASN C 448VAL C 401SER C 438TYR C 508 | 1.66A | 15.9916.74 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 8 | TYR C 396PHE C 338VAL C 524SER C 359 | 1.68A | 15.9916.74 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w4h | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.42A | 17.81 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.45A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7070LEU A7010ILE A7080MET A7058 | 1.55A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7078LEU A7072ASN A7066ILE A7065 | 1.52A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6852LEU C6857ASN C7008MET C6982 | 1.44A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.43A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7078LEU C7072ASN C7066ILE C7065 | 1.56A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7070LEU C7010ILE C7080MET C7058 | 1.49A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7078LEU A7072ASN A7066ILE A7065 | 1.55A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7070LEU A7010ILE A7080MET A7058 | 1.51A | 22.98 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 121LEU A 35LEU A 55ILE B 120 | 1.70A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 116LEU A 56LEU B 103ILE B 120 | 1.47A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU F 331LEU E 339ASN E 354ILE E 357 | 1.59A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU E 331LEU F 339ASN F 354ILE F 357 | 1.35A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU B 331LEU A 339ASN A 354ILE A 357 | 1.42A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU A 331LEU B 339ASN B 354ILE B 357 | 1.53A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU D 331LEU C 339ASN C 354ILE C 357 | 1.39A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | LEU C 331LEU D 339ASN D 354ILE D 357 | 1.56A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU C6852LEU C6857ASN C7008MET C6982 | 1.40A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7070LEU A7010ILE A7080MET A7058 | 1.51A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7078LEU A7072ASN A7066ILE A7065 | 1.56A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.43A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU C7070LEU C7010ILE C7080MET C7058 | 1.49A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU C7078LEU C7072ASN C7066ILE C7065 | 1.56A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | ASN D 75PHE D 53SER D 51TYR D 111 | 1.73A | 14.9519.50 | MES D 201 (-3.0A)NoneNoneNone | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | ASN C 75PHE C 53SER C 51TYR C 111 | 1.61A | 14.9519.50 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | ASN B 75PHE B 53SER B 51TYR B 111 | 1.62A | 14.9519.50 | MES B 201 (-3.1A)NoneNoneNone | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | ASN A 75PHE A 53SER A 51TYR A 111 | 1.53A | 14.9519.50 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7070LEU A7010ILE A7080MET A7058 | 1.50A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7070LEU C7010ILE C7080MET C7058 | 1.49A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6852LEU C6857ASN C7008MET C6982 | 1.40A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7078LEU C7072ASN C7066ILE C7065 | 1.55A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.43A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7078LEU A7072ASN A7066ILE A7065 | 1.56A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | ASN A 20HIS D 119VAL D 82SER D 80 | 1.29A | 16.7716.59 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | ASN C 20HIS B 119VAL B 82SER B 80 | 1.32A | 16.7716.59 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7078LEU A7072ASN A7066ILE A7065 | 1.57A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7070LEU A7010ILE A7080MET A7058 | 1.60A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6852LEU A6857ASN A7008MET A6982 | 1.45A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 121LEU A 35LEU A 55ILE B 120 | 1.75A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 116LEU A 56LEU B 103ILE B 120 | 1.36A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO D 121LEU C 35LEU C 55ILE D 120 | 1.73A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO D 116LEU C 56LEU D 103ILE D 120 | 1.37A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 7 | TRP A 93LEU A 117LEU A 120ILE A 151 | 1.77A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | PRO D 116LEU C 56LEU D 103ILE D 120 | 1.37A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | PRO B 116LEU A 56LEU B 103ILE B 120 | 1.41A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | PRO B 121LEU A 35LEU A 55ILE B 120 | 1.66A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | PRO D 121LEU C 35LEU C 55ILE D 120 | 1.68A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | ASN E 448VAL E 401SER E 438TYR E 508 | 1.72A | 16.9318.45 | NoneNoneNoneDMS E 902 (-4.0A) | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR A 451PHE A 497VAL A 510TYR A 508 | 1.64A | 16.9318.45 | NoneNoneNoneDMS A 903 (-3.5A) | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 396PHE E 338VAL E 524SER E 359 | 1.61A | 16.9318.45 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | HEAVY CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR A 369PHE A 377VAL A 382SER B 100 | 1.61A | 16.9318.45 | NoneNoneDMS A 905 (-4.3A)None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR A 396PHE A 338VAL A 524SER A 359 | 1.73A | 16.9318.45 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 451PHE E 497VAL E 510TYR E 508 | 1.64A | 16.9318.45 | NoneNoneNoneDMS E 902 (-4.0A) | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | HEAVY CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR E 369PHE E 377VAL E 382SER H 100 | 1.63A | 16.9318.45 | NoneNoneDMS L1601 (-4.2A)None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR A 451PHE A 497SER A 438TYR A 508 | 1.66A | 16.9318.45 | NoneNoneNoneDMS A 903 (-3.5A) | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 396PHE E 338VAL E 524SER E 359 | 1.63A | 16.9318.45 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 451PHE E 497VAL E 510TYR E 508 | 1.64A | 16.9318.45 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | ASN A 151PHE A 112VAL A 125TYR A 126 | 1.80A | 21.7120.17 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 451PHE E 497VAL E 510TYR E 508 | 1.63A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR A 451PHE A 497VAL A 510TYR A 508 | 1.64A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR E 396PHE E 338VAL E 524SER E 359 | 1.60A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | IGG H CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR A 369PHE A 377VAL A 382SER B 100 | 1.63A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | IGG H CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR A 489ASN A 487PHE H 150VAL H 117 | 1.64A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | ASN A 448VAL A 401SER A 438TYR A 508 | 1.72A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | TYR A 396PHE A 338VAL A 524SER A 359 | 1.60A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | ASN E 448VAL E 401SER E 438TYR E 508 | 1.71A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yor | IGG H CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 8 | TYR E 369PHE E 377VAL E 382SER H 100 | 1.63A | 17.0718.70 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | ASN A 151PHE A 112VAL A 125TYR A 126 | 1.80A | 21.7120.17 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | TRP A 162LEU A 131LEU A 247ILE A 171 | 1.47A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO D 116LEU C 56LEU D 103ILE D 120 | 1.46A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | TRP A 509LEU A 372LEU A 527ILE A 562 | 1.62A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 275PHE A 326HIS A 347VAL A 353 | 1.77A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 192PHE A 219HIS A 99TYR A 217 | 1.57A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 745PHE A 741VAL A 720TYR A 719 | 1.78A | 19.4720.38 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 748ASN A 703PHE A 745PHE A 471 | 1.79A | 19.4720.38 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 121LEU A 270LEU A 271ILE B 120 | 1.69A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 619ASN A 695PHE A 753VAL A 785 | 1.66A | 19.4720.38 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | PRO D 121LEU C 35LEU C 55ILE D 120 | 1.75A | None | |||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | TRP A 162LEU A 131LEU A 247ILE A 171 | 1.53A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 275PHE A 326HIS A 347VAL A 353 | 1.79A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 192PHE A 219HIS A 99TYR A 217 | 1.70A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | ASN A 314PHE A 326HIS A 347TYR A 346 | 1.69A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 619ASN A 695PHE A 753VAL A 785 | 1.67A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 192PHE A 219HIS A 99TYR A 217 | 1.72A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | ASN A 314PHE A 326HIS A 347TYR A 346 | 1.70A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 745PHE A 741VAL A 720TYR A 719 | 1.75A | 18.8720.47 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | TRP A 162LEU A 131LEU A 247ILE A 171 | 1.50A | None | |||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | PHE A 275PHE A 326HIS A 347VAL A 353 | 1.76A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 619ASN A 695PHE A 753VAL A 785 | 1.67A | 18.8720.47 | None | ||
![]() | 6HUO_D_08HD501_0 (GAMMA-AMINOBUTYRICACID RECEPTORSUBUNITALPHA-1,GAMMA-AMINOBUTYRIC ACID RECEPTORSUBUNIT ALPHA-1GAMMA-AMINOBUTYRICACID RECEPTORSUBUNIT GAMMA-2) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | TYR A 748ASN A 703PHE A 745PHE A 471 | 1.79A | 18.8720.47 | None | ||
![]() | 3U5J_A_08HA1_1 (BROMODOMAIN-CONTAINING PROTEIN 4) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | PRO B 121LEU A 270LEU A 271ILE B 120 | 1.66A | None |